What the boxed warning actually says
The boxed warning is specific. It says semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, but that it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.
That distinction matters. It gives users an accurate reason to pay attention without crossing into exaggerated copy that says the drug is proven to cause broad cancer outcomes in people.
References For This Section
Who should speak with a clinician promptly
The current label says Wegovy is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. MedlinePlus also tells patients to discuss that history and to contact a doctor if they develop a neck lump, hoarseness, trouble swallowing, or shortness of breath.
That makes this page most useful when it helps someone understand the scope of the warning, recognize the family-history issue, and know which symptoms should be checked promptly.
References For This Section
Why this page avoids broader cancer claims
A lot of low-quality pages flatten this entire topic into 'semaglutide causes cancer.' That is not what the boxed warning says. The accurate public-source position is narrower and should stay narrower.
If someone later wants a review, the relevant details are the product used, timing, personal or family thyroid history, what symptoms or findings were documented, and what clinicians said about the issue.
References For This Section